A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma

This study has been completed.

Study NCT00452699 Information provided by GlaxoSmithKline

First Received on March 26, 2007. Last Updated on November 10, 2011 History of Changes

Results First Received: January 14, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Asthma
Interventions:	Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID Drug: Fluticasone propionate 250 mcg BID

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
FSC DISKUS 250/50 Mcg BID for 52 Weeks	Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks
FP DISKUS 250 Mcg BID for 52 Weeks	Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks

Participant Flow: Overall Study

	FSC DISKUS 250/50 Mcg BID for 52 Weeks	FP DISKUS 250 Mcg BID for 52 Weeks
STARTED	306	315
COMPLETED	225	242
NOT COMPLETED	81	73
Adverse Event	10	3
Lack of Efficacy	6	4
Lost to Follow-up	6	9
Protocol Violation	21	25
Withdrawal by Subject	26	25
Other	12	7

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
FSC DISKUS 250/50 Mcg BID for 52 Weeks	Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks
FP DISKUS 250 Mcg BID for 52 Weeks	Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks

Baseline Measures

	FSC DISKUS 250/50 Mcg BID for 52 Weeks	FP DISKUS 250 Mcg BID for 52 Weeks	Total
Number of Participants [units: participants]	306	315	621
Age [units: years] Mean ± Standard Deviation	36.8 ± 15.52	39.3 ± 15.52	38.1 ± 15.55
Gender [units: participants]
Female	191	201	392
Male	115	114	229
Race/Ethnicity, Customized [units: participants]
White	197	208	405
African American	63	61	124
Asian	39	41	80
American Indian	3	4	7
Other	4	1	5

Outcome Measures

Show All Outcome Measures

1. Primary:

Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]

Show Outcome Measure 1

2. Secondary:

Mean Change From Baseline in AM PEF Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]

Show Outcome Measure 2

3. Secondary:

Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52 [ Time Frame: Baseline and Week 1 through Week 52 ]

Show Outcome Measure 3

4. Secondary:

Rate of Asthma Attacks Per Participant Per Year [ Time Frame: Week 1 through Week 52 ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343

No publications provided

Responsible Party:	Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier:	NCT00452699 History of Changes
Other Study ID Numbers:	ADA109055
Study First Received:	March 26, 2007
Results First Received:	January 14, 2010
Last Updated:	November 10, 2011
Health Authority:	United States: Food and Drug Administration; Canada: Health Canada